Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ASND Ascendis Pharma AS

144,08

1,59 (1,12%)

14 Feb 2025 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
Von Jan 2025 bis Feb 2025

Click Here for more Ascendis Pharma AS Charts.

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
Von Feb 2024 bis Feb 2025

Click Here for more Ascendis Pharma AS Charts.

News Ascendis Pharma AS

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 12 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 12 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Mittwoch 12 Februar 2025 (4 Tage vor) • GlobeNewswire Inc.

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Mittwoch 12 Februar 2025 (4 Tage vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 12 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
Mittwoch 5 Februar 2025 (2 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 15 Januar 2025 (1 Monat vor) • Edgar (US Regulatory)

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
Sonntag 12 Januar 2025 (1 Monat vor) • GlobeNewswire Inc.

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Montag 6 Januar 2025 (1 Monat vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 30 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
Donnerstag 19 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 17 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Ascendis Pharma AS News-Artikel

Financial Select Sector

Health Care Select Sector

Deutsche Lufthansa

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen